Intravitreal injections of anti-VEGF antibodies, such as bevacizumab, are widely used in treatments to reduce angiogenesis based on studies that have reported VEGF expression upregulation in ischemic conditions such as AMD and diabetic retinopathy [10,11]. The gene discussed is VEGFA; the disease is diabetic retinopathy.